Should embryonic stem cell research and somatic cell-cloned embryo research be banned?

In this blog post, I will examine the potential of embryonic stem cell research for treating diseases, its differences from other stem cell technologies, its value to the biotechnology industry, and issues related to bioethics and safety. I will also consider the appropriate limits for permitting embryonic stem cell research and somatic cell-cloned embryo research.

 

In the past, Advanced Cell Technology, a U.S.-based stem cell therapy company, garnered significant attention for conducting early-stage clinical trials in which retinal pigment epithelial cells derived from human embryonic stem cells were transplanted into patients with age-related macular degeneration and Stargardt disease. In that study, which involved 18 patients, subretinal pigment changes presumed to be related to the transplanted cells were observed in 13 patients, and vision improved in 10 of the 18 treated eyes. However, since the primary objective of this study was to evaluate safety and tolerability rather than to confirm therapeutic efficacy, these results should not be interpreted as direct evidence that embryonic stem cells cured blindness. Furthermore, in 2013, researchers at the University of Wisconsin–Madison transplanted neural progenitor cells derived from human embryonic stem cells into the brains of mice with damaged neural circuits involved in learning and memory, and confirmed that some learning and memory functions improved as a result. Since then, stem cell research has advanced further: in clinical trials for Type 1 diabetes using islet cells derived from stem cells, some participants were able to regulate their blood sugar levels without external insulin administration; and in Parkinson’s disease, early-stage clinical trials are underway involving the transplantation of dopamine neural progenitor cells derived from human embryonic stem cells. Although a significant portion of this research is still at a stage where long-term safety and therapeutic efficacy must be further verified, it is clear that pluripotent stem cells, including embryonic stem cells, serve as a crucial foundation for regenerative medicine research. On the other hand, opponents of embryonic stem cell research argue that the process of obtaining cells from embryos may conflict with the moral status of human life, and that safety concerns—such as tumor formation and immune rejection—must be thoroughly examined. These concerns are by no means trivial. However, considering that embryonic stem cells possess unique research characteristics that distinguish them from other stem cells and are being utilized as a crucial means of exploring potential treatments for various intractable diseases, it is necessary to consider continuing research under strict ethical and legal controls rather than imposing a blanket ban on embryonic stem cell research and limited somatic cell nuclear transfer embryo research for therapeutic purposes.
First, research using embryonic stem cells has great potential to contribute to the advancement of cutting-edge medicine and regenerative medicine. Ever since humans first appeared in history, disease has been a challenge that humanity has constantly sought to overcome. Although medicine has advanced by leaps and bounds throughout modern and contemporary history, there are still many diseases that are difficult to cure completely or for which existing treatments alone are insufficient. To address these diseases, it is necessary to explore and validate various treatment methods based on scientific evidence. Of course, if research with slim prospects is pursued without proper review, it could result in a massive waste of research funds and human resources; therefore, an objective scientific evaluation must be conducted first. However, in the field of pluripotent stem cell research—including embryonic stem cells—clinical studies are already underway to differentiate human cells into cells with specific functions for use in treating diseases. In Type 1 diabetes, research is underway to enable islet cells derived from stem cells to secrete insulin within the body, and in Parkinson’s disease, clinical trials are being conducted to transplant stem cell-derived neural progenitor cells to compensate for the function of damaged or lost dopamine neurons. In the field of ophthalmology, research is also continuing to treat age-related macular degeneration and hereditary retinal diseases using retinal pigment epithelial cells derived from embryonic stem cells and induced pluripotent stem cells. As such, stem cell technology has moved beyond the stage of animal experiments and, in some fields, has entered the phase of verifying safety and efficacy in actual patients through early-stage clinical trials. However, the technology to mass-produce fully functional organs for transplantation using only embryonic stem cells—as was once anticipated—is not yet a standard medical practice. Currently, research focused on creating specific cells, tissues, and organoids is at a more realistic stage, while the technology to safely produce and transplant entire organs still faces many challenges. Nevertheless, if stem cell research advances further to the point where it can regenerate damaged tissue or reliably supply transplantable cells and tissues, it could offer new options to patients who have been denied treatment opportunities due to a lack of available organs or tissues. Ultimately, the value of embryonic stem cell research does not lie in the ability to cure all diseases, but in expanding the possibilities for treating conditions that were previously difficult to address with conventional medicine. If such research undergoes sufficient validation and develops into safe and effective treatments, it will not only extend human life but also contribute to restoring the quality of life impaired by disease and preserving human dignity.
Furthermore, embryonic stem cell research has characteristics that make it difficult to view it as entirely identical to other forms of stem cell research. Opponents of embryonic stem cell research question the necessity of using embryonic stem cells when the ethical issue of destroying embryos can be avoided by using adult stem cells or induced pluripotent stem cells (iPS cells). In fact, research using adult stem cells and iPS cells is currently being conducted very actively. Adult stem cells are found in various tissues, including bone marrow and blood, and serve to replenish damaged or lost cells. They generally possess the ability to differentiate into cell types associated with specific tissues, and some, such as hematopoietic stem cells, are already used in established medical treatments. Meanwhile, iPS cells are cells created by reprogramming mature somatic cells—such as skin or blood cells—to restore their pluripotency. In the past, it was commonly claimed that iPS cells had significantly lower differentiation potential than embryonic stem cells; however, both embryonic stem cells and iPS cells are now classified as pluripotent stem cells capable of differentiating into various cell types that make up the human body. Therefore, it is inappropriate to explain the difference between the two simply by stating that one has superior differentiation potential. iPS cells offer a significant advantage in that they can be derived from the patient’s own cells without the use of embryos, and they are widely utilized in the creation of disease models, new drug development, and cell therapy research. On the other hand, genetic and epigenetic changes that may occur during the reprogramming and culture processes, variations between cell lines, and the complexity of the manufacturing process remain challenges that require ongoing management. Embryonic stem cells are also not free from issues such as immune rejection, the potential for abnormal proliferation if undifferentiated cells remain, and ethical concerns surrounding the use of embryos. Ultimately, it is more accurate to view adult stem cells, iPS cells, and embryonic stem cells not as simple substitutes for one another, but as research resources, each with its own characteristics, strengths, and weaknesses. The key point is not to argue that embryonic stem cells are always superior to other types of stem cells, but rather that, in certain research contexts, embryonic stem cells still serve as an important benchmark and research resource, and it is difficult to conclude that other technologies alone can replace them for all research purposes. Therefore, while actively developing alternative technologies to mitigate ethical concerns, it would be reasonable to advance research in a direction that leverages the strengths of each type of stem cell and minimizes their risks, rather than imposing a blanket ban on embryonic stem cell research where scientific necessity is recognized.
Furthermore, it is necessary to consider the significance of stem cell research in light of the fact that the biotechnology industry and regenerative medicine are emerging as key sectors of the future. In the past, interest in biotechnology within the South Korean industrial sector grew significantly as major corporations, including the Samsung Group, identified the bioindustry as a new growth sector. Since then, biopharmaceuticals, cell therapies, gene therapies, tissue engineering, organoids, and regenerative medicine have indeed grown into research and development fields that have attracted long-term investment from countries and companies around the world. Stem cell research is also one of the key fields driving this trend. Since the initial establishment of human embryonic stem cells, various countries have established different regulatory frameworks regarding the scope of permitted research and ethical standards. Even in countries where such research is permitted, it is generally not the case that embryos can be used without any restrictions; rather, research purposes, the source of embryos, researcher consent procedures, and ethical review are strictly regulated. In the United States as well, federal funding policies for human embryonic stem cell research have evolved over a long period amid political and ethical debates; however, research on pluripotent stem cells—including human embryonic stem cells and iPS cells—continues. At the same time, there has recently been a growing movement to actively identify areas where embryos can be replaced with technologies such as iPS cells and adult stem cells. This demonstrates that embryonic stem cell research and the development of alternative technologies need not be viewed as mutually exclusive options. Because advances in biotechnology and medicine directly involve human life and the human body, scientific possibilities often clash with ethical boundaries. However, halting all research that has the potential to raise ethical controversies could unduly limit opportunities to develop new treatments. Conversely, ethical concerns should not be treated as secondary simply for the sake of economic value or technological competition. Embryonic research cannot be justified solely on the grounds of enhancing the competitiveness of the biotechnology industry; rather, the scientific necessity of the research, social benefits, ethical justification, and the protection and safety of research subjects must all be considered together. Therefore, the industrial potential of embryonic stem cell research should not be viewed as the sole justification for permitting such research, but rather as one of the reasons to continue research that meets medical needs and adheres to ethical standards.
It is also necessary to reflect deeply once again on the bioethical issues surrounding embryonic stem cells. First, embryonic stem cell research and human reproductive cloning are not the same concept. Human embryonic stem cells generally derive from pre-implantation-stage embryos, and a distinction must be made between research that establishes stem cell lines using embryos created through somatic cell nuclear transfer and reproductive cloning, which aims to give birth to cloned humans. South Korea’s current Bioethics Act also prohibits human reproductive cloning—that is, implanting somatic-cell-cloned embryos into the uterus of a human or animal to sustain a pregnancy or give birth. On the other hand, research on somatic-cell-cloned embryos is permitted only under limited purposes and procedures stipulated by law—such as research aimed at treating rare or intractable diseases—and is subject to controls, including registration of research institutions and approval of research plans. Therefore, the argument that “cloning” of embryonic stem cells should be permitted should not be equated with the argument that the cloning of human individuals should be permitted. Furthermore, while the criterion of “14 days after fertilization” was widely used in the past regarding human embryo research, today this criterion itself is being scrutinized in detail alongside scientific advancements. The International Society for Stem Cell Research emphasizes the need for rigorous scientific and ethical review of embryonic research and maintains that research involving culture beyond 14 days may be considered only under special review, provided that it is permitted by the laws and social consensus of the relevant country. Ultimately, determining at what point an embryo should be accorded a certain degree of moral status is a philosophical, religious, and social issue that cannot be resolved by science alone. Just as various Buddhist traditions place great importance on non-violence and caution against acts that harm life, judgments regarding embryonic research may vary depending on where individuals or communities draw the line regarding the beginning of life. However, this issue cannot be left entirely to individual preference. This is because research involves standards that require societal consensus, such as the consent of embryo donors, the necessity of the research, the obligation to minimize the use of embryos, and patient safety. Meanwhile, we must also give due consideration to the issue of healthcare inequality—namely, the possibility that when treatments using embryonic stem cells are developed, only some patients may benefit due to cost barriers. However, rather than banning the research itself merely because new technologies carry the potential for inequality, it may be more appropriate to establish policies and systems that promote equitable access as the research progresses toward actual treatments. The same applies to safety. We must not equate the high failure rates and developmental abnormalities observed in past cases of animal reproductive cloning with the side effects of embryonic stem cell therapy. The primary risks that must be managed in embryonic stem cell-based therapies include the potential for abnormal proliferation or tumor formation due to undifferentiated cells, immune rejection, and complications arising from transplantation surgery and immunosuppressive therapy. While these risks are by no means trivial, it is precisely for this reason that safety must be verified through clinical trials and long-term follow-up. Rather than ruling out research possibilities from the outset merely because side effects are a potential risk, the fundamental approach to scientific research should be to objectively compare the level of risk with the potential benefits of treatment, and to manage the situation by halting research or refining methods if unacceptable risks are identified.
In summary, considering the therapeutic potential of embryonic stem cells for various diseases, their unique research characteristics—which differ from those of other stem cells—and their potential for advancement in regenerative medicine and the biotechnology industry, it seems more reasonable to permit necessary research under strict ethical and legal oversight rather than imposing a blanket ban on embryonic stem cell research and limited somatic cell cloning research for therapeutic purposes. This does not mean, however, that all forms of embryo research and cloning should be permitted. In particular, reproductive cloning—which aims to give birth to cloned humans—must be clearly distinguished from embryonic stem cell research or somatic cell cloning research for therapeutic purposes, and is currently prohibited by law in South Korea. The controversy surrounding embryonic stem cell research is likely to become even more complex as science advances. It is difficult to provide a simple answer based on a single set of values regarding where to draw the line in recognizing the moral status of an embryo, to what extent embryos can be used as research subjects to treat diseases, and how to evaluate the risks and benefits of new therapeutic technologies. Therefore, rather than concluding that one side is absolutely right and the other wrong, we must collectively assess which research is scientifically necessary, what benefits it can bring to patients and society, and to what extent the ethical costs and risks involved in the process can be minimized. Since embryonic stem cell research is a field directly linked to human life, it must not be conducted indiscriminately solely for economic gain or technical curiosity, nor should it expand into socially unacceptable areas such as human reproductive cloning. At the same time, it is important to strike a balance between scientific necessity, bioethics, patient safety, and social consensus to ensure that legitimate research is not blocked, thereby preserving the opportunity to explore potential treatments. Ultimately, the core question surrounding embryonic stem cell research goes beyond simply whether to allow or prohibit it. The more important issue is to continually deliberate on the extent to which such research should be permitted and under what conditions and oversight it should be conducted—so as to protect human life and dignity while preserving the potential for medical advancement.

 

About the author

Cam Tien

I love things that are gentle and cute. I love dogs, cats, and flowers because they make me happy. I also enjoy eating and traveling to discover new things. Besides that, I like to lie back, take in the scenery, and relax to enjoy life.